ERBB2 and breast carcinoma: So far, the evaluation of HER2 status in breast carcinoma patients mainly relies on immunohistochemistry (IHC) examination after surgical tumor excision or biopsy [13], whereas both biopsy and surgery are invasive procedures and may lead to an increased risk of complications such as seroma, local pain, and infection [14,15].